⌕
Scholar Rock Holding · SRRK · Nasdaq
Tenet 25 · Weak
Compare
$44.54+3.09%At closeTenet 25 · Weak
$44.54+1.34 (+3.09%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Scholar Rock Holding (SRRK) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 16, 2026 · 12:52 ET
Scholar Rock Holding Corporation (SRRK) Presents at UBS Global Biopharma Conference 2026 Transcript

Scholar Rock Holding Corporation ( SRRK ) UBS Global Biopharma Conference 2026 November 16, 2026 5:00 AM EST Company Participants David Hallal - CEO & Chairman of the Board Conference Call Participants Michael Yee - UBS …

● Business WireNov 13, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 39,587 shares of its common stock to six newly hire…

● MarketBeatNov 10, 2026 · 13:17 ET
What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

Scholar Rock NASDAQ: SRRK reported $0.6 million in third-quarter revenue from initial shipments of its newly approved spinal muscular atrophy treatment ISEMBYLD, while executives said insurance and reimbursement hurdles …

● Seeking AlphaNov 10, 2026 · 13:01 ET
Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript

Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 10, 2026 · 09:05 ET
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates

Scholar Rock Holding Corporation (SRRK) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.9 per share a year ago.…

● Business WireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its l…

● GuruFocusOct 20, 2026 · 08:00 ET
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets…

● Business WireOct 16, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly hi…

● Business WireOct 8, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its l…

● Defense WorldOct 7, 2026 · 08:21 ET
Scholar Rock (NASDAQ:SRRK) Stock Falls 5.1% – Here’s What Happened

Shares of Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) traded down 5.1% on Monday. The stock traded as low as $44.59 and last traded at $44.4380. Approximately 908,652 shares were traded during mid-d…

● PRNewsWireSep 30, 2026 · 09:56 ET
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK)  breached their fiduciary d…

● Business WireSep 21, 2026 · 12:00 ETCOMPANY'S OWN WORDS
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common stock to ten newly hire…

● Defense WorldSep 18, 2026 · 03:13 ET
Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LP

Engineers Gate Manager LP lifted its stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) by 211.3% during the second quarter, according to the company in its most recent disclosure with the Securities and …

● Seeking AlphaSep 15, 2026 · 15:11 ET
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

Scholar Rock Holding Corporation maintains a "Strong Buy" rating following FDA approval of ISEMBYLD [apitegromab] for SMA in patients ≥2 years old. SRRK targets a $2B+ market opportunity in SMA, with expansion potential …

● Seeking AlphaSep 14, 2026 · 15:01 ET
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript…

● BenzingaSep 14, 2026 · 09:24 ET
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock (NASDAQ:SRRK) for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and older.…

● ReutersSep 14, 2026 · 08:38 ET
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

Scholar Rock on Monday ​set a list ‌price of $11,659 per single-use vial ​for its ​newly approved spinal muscular ⁠atrophy drug, ​the first therapy ​that directly targets muscle loss in ​patients with ​the rare genetic d…

● BenzingaSep 14, 2026 · 05:50 ET
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the company announced the FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted treatment for children …

● Business WireSep 11, 2026 · 18:25 ETCOMPANY'S OWN WORDS
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its l…

● ReutersSep 11, 2026 · 17:27 ET
US FDA approves Scholar Rock's muscle weakness drug

The ​U.S. Food ‌and Drug ​Administration ​on Friday ⁠approved ​Scholar ​Rock's therapy to ​treat ​a rare ‌genetic ⁠condition that causes ​muscle ​weakness.…

● Seeking AlphaSep 10, 2026 · 12:57 ET
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

● Seeking AlphaSep 7, 2026 · 10:23 ET
Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise

Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for SMA, pending FDA approval by September 30, 2026. Manufacturing setbacks were production-based, not due to drug efficacy or safety;…

● Business WireSep 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its w…

● Defense WorldAug 31, 2026 · 04:10 ET
Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK

Beaconlight Capital LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissi…

● Business WireAug 21, 2026 · 09:06 ETCOMPANY'S OWN WORDS
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its w…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just SRRK · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.